reports
ASM share buyback update May 15 – 17, 2024
ASM share buyback update May 15 – 17, 2024 Almere, The Netherlands May 21, 2024, 5:45 p.m. CET ASM International N.V. (Euronext Amsterdam: ASM) reports the following transactions, conducted under ASM's current share buyback program. DateRepurchased sharesAverage priceRepurchased valueMay 15, 20245,161€ 628.21€ 3,242,172May 16, 20244,800€ 651.96€ 3,129,395May 17, 20245,200€ 647.43€ 3,366,635Total15,161€ 642.32€ 9,738,202 These repurchases were made as part of the €150 million share buyback program which started on May 15, 2024. Of the total program, 6.5% has been repurchased. For further de...
- Pierre FerraguÊ
Bible 1Q24 – Semicap: recovery on track, positive 2025 outlook in expe...
Today, we are publishing the Semicap section of our 23rd Tech Infrastructure Quarterly Bible. The Tech Bible is a must-read for any tech investor, as it summarizes the quarterly earnings reports from the over 130 companies we track, providing an update on our key perspectives and convictions. In the coming weeks we will publish sections on Automotive, Cloud Infrastructure, Telecom Equipment, Industrials, PCs, Enterprise IT, and Ride sharing & Delivery. Semicap equipment revenues were in line wi...
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-clas...
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration Paris, New York, N.Y., and San Francisco, CA, May 21, 2024. Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within...
Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une c...
Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA Paris, New York, New York et San Francisco, Californie, 21 mai 2024. Sanofi, Formation Bio et OpenAI collaborent afin de construire des logiciels alimentés par l’IA afin d’accélérer le développement de médicaments et de proposer de nouveaux médicaments aux patients de manière plus efficace. Les trois équipes réuniront des données, des logiciels et des modèles adaptés pour développer d...
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares - April 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry un...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory ph...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in mo...
Communiqué de presse : Présentation à l’ATS et publication dans le NEJ...
Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCO Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCO Les résultats de l’étude NOTUS confirment les données décisives de l’étude de phase III BOREAS et montrent que, dans le traitement de la bronchopneumopathie chronique obstructive (BPCO) avec signature inflammatoire de ty...
STMicroelectronics Announces Status of Common Share Repurchase Program
STMicroelectronics Announces Status of Common Share Repurchase Program STMicroelectronics Announces Status ofCommon Share Repurchase Program Disclosure of Transactions in Own Shares – Period from May 13, 2024 to May 17, 2024 AMSTERDAM – May 20, 2024 -- STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated July 1, 2021. The Program was approved by a shareholder resolution...
- Research Department
INFORME DIARIO 20 MAYO (ANÁLISIS BANCO SABADELL)
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACERINOX, IBERDROLA, TALGO, TELEFÓNICA. EUROPA: ASML. Buena semana para la periferia europea y EE.UU. Semana de avances de hasta el +2,0% en la periferia europea y de nuevos máximos anuales en el S&P 500, beneficiadas por la decepción en los datos macro y el recorte en la rentabilidad de la deuda. Dentro del STOXX 600, lideraron las ganancias semanales los sectores Telecos e Inmobiliario (c. +3,0%) mientras que Energía y Viajes&Ocio terminaron con l...
LNA Sante Sa: 1 director
A director at LNA Sante Sa bought 34,000 shares at 20.800EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
EQS-News: Convocation of the Annual General Meeting
EQS-News: ams-OSRAM AG / Key word(s): AGM/EGM Convocation of the Annual General Meeting 17.05.2024 / 14:41 CET/CEST The issuer is solely responsible for the content of this announcement. ams-OSRAM AG Premstätten, FN 34109 k ISIN AT0000A18XM4 ("Company") Convocation of the Annual General Meeting We hereby invite our shareholders to attend the Annual General Meeting of ams-OSRAM AG on Friday, June 14, 2024, at 10:00 a.m, on the Company’s premises in 8141 Premstätten, Tobelbader Straße 30. I. Agenda Presentation of the annual financial statements includ...
EQS-News: ams-OSRAM AG: Einberufung der ordentlichen Hauptversammlung ...
EQS-News: ams-OSRAM AG / Schlagwort(e): Hauptversammlung ams-OSRAM AG: Einberufung der ordentlichen Hauptversammlung 2024 17.05.2024 / 14:41 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. ams-OSRAM AG Premstätten, FN 34109 k ISIN AT0000A18XM4 (“Gesellschaft”) Einberufung der ordentlichen Hauptversammlung Wir laden hiermit unsere Aktionärinnen und Aktionäre ein zur ordentlichen Hauptversammlung der ams-OSRAM AG am Freitag, den 14. Juni 2024, um 10:00 Uhr, in 8141 Premstätten, Tobelbader Straße 30, in den Räumen der Ge...
- Carole Braudeau
- Carole Braudeau
- Michael B. Schäfer
ODDO BHF Small & MIDCAP MORNING NEWS - 05/17/2024
Growth momentum remains solid, and the publication of Q1 sales bodes well for the future (12.5% organic growth, including 27% for Aerospace). Margins are set to pick up in 2024 (by an estimated 110bp), with the underlying operating profit expected to jump 33%. With good visibility for Aerospace, medium-term potential for Automotive and profitable growth for Medical, we estimate the potential for margin improvement at no less than 500bp in the medium term. We are raising our underlying...
DBG DERICHEBOURG SA
ALCAR CARMAT SA
TPE PVA TEPLA AG
NEX NEXANS SA
ERG ERG S.P.A.
WIE WIENERBERGER AG
GREEN GREENYARD NV
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
NVG NAVIGATOR COMPANY SA
COL INMOBILIARIA COLONIAL SOCIMI SA
SIFG SIF HOLDING NV
TMV TEAMVIEWER AG
VK VALLOUREC SA
FPE3 FUCHS PETROLUB SE
- Michael B. Schäfer
ODDO BHF Small & MIDCAP MORNING NEWS - 17/05/2024
La dynamique de croissance reste solide et la publication du CA T1 est de bon augure (croissance organique de 12.5% dont 27% pour l’Aerospace). 2024 devrait voir un redressement des marges (+110 pb estimés) pour un ROC attendu en hausse de 33%. A l’appui d’une bonne visibilité pour l’aéronautique, d’un potentiel MT pour l’automobile et d’une croissance profitable pour le Médical, nous estimons le potentiel d’amélioration des marges à au moins 500 pb à MT. Nous relevons nos estimations...
DBG DERICHEBOURG SA
ALCAR CARMAT SA
TPE PVA TEPLA AG
NEX NEXANS SA
ERG ERG S.P.A.
WIE WIENERBERGER AG
GREEN GREENYARD NV
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
NVG NAVIGATOR COMPANY SA
COL INMOBILIARIA COLONIAL SOCIMI SA
SIFG SIF HOLDING NV
TMV TEAMVIEWER AG
VK VALLOUREC SA
FPE3 FUCHS PETROLUB SE
- Maissa Keskes
- Stephane Houri
PVA Tepla : Multiple growth drivers that support the 2028 targets
>Outperform rating and target price of € 35 maintained - PVA Tepla held its first CMD at its headquarter in Wettenberg yesterday. The CMD bolsters the group’s structural growth status with its exposure to multiple growth markets. It also enabled us to better comprehend the strategy and vision out to 2028. We see the group as offering a robust growth story on several fronts, with notably SiC as a driver (between 20% and 25% of the group’s orders), its Metrology divisio...
- Maissa Keskes
- Stephane Houri
PVA Tepla : De multiples leviers de croissance qui soutiennent les obj...
>Opinion Surperformance et OC à 35 € maintenus - PVA Tepla a organisé hier son premier CMD dans son siège à Wettenberg. Ce CMD vient conforter le statut de croissance structurelle du groupe exposé à des multiples marchés en croissance. Il nous a également permis de mieux appréhender la stratégie et la vision jusqu’à 2028. Le groupe dispose, selon nous, d’une histoire de croissance solide sur plusieurs fronts, avec notamment le SiC comme moteur (20-25% des commandes du...
Vat Group Ag: 1 director
A director at Vat Group Ag sold 325 shares at 476.000CHF and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
- Pierre FerraguÊ
Infineon: Microcontroller share gains help offset the cyclical slowdow...
Infineon’s auto MCU revenues have nearly tripled in the last four years, with market share increasing from 16% to 29%. The company has good visibility on further growth, and we expect this, along with growth in xEVs, to offset the cyclical slowdown this year and contribute to double-digit growth beyond. Infineon is one of our top picks this year. The largest round of downward revisions is behind us, and the stock is attractively valued, ahead of another leg of strong secular growth beyond this y...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.